A landmark achievement in public health has been announced, with zero deaths from cervical cancer recorded among women aged 20 to 24 in England between 2020 and 2024. This unprecedented five-year period marks the first time such a statistic has been observed and is being hailed as a direct triumph of the Human Papillomavirus (HPV) vaccination programme.
The HPV vaccine, first introduced in the UK for girls aged 12 or 13 in 2008 and extended to boys in 2019, targets the virus responsible for almost all cervical cancers. Experts from Queen Mary University of London, who have been monitoring cervical cancer rates and deaths, described the results as 'stunning'. Historically, around 23 deaths would have been expected in this age group over the same period, underscoring the dramatic impact of the vaccine.
This research is significant as it provides the first direct evidence that the HPV vaccine prevents cervical cancer-related deaths, building on previous findings that showed its effectiveness in reducing HPV infections and the incidence of cervical cancer. Concerns had existed that the vaccine might primarily prevent cancers that would have been detected early through screening, rather than those more likely to be missed and prove fatal. Fortunately, these latest findings suggest this is not the case.
The success is largely attributed to the high uptake of the vaccine, with approximately 90% of women in England aged 20 to 24 having received the jab during their early teenage years. Beyond cervical cancer, the HPV vaccine also offers protection against other HPV-related cancers, including those affecting the mouth, anus, throat, and penis, as well as warts in various areas for both sexes.
While the immediate focus is on the 20-24 age group, researchers estimate that around 200 lives have already been saved across all age groups, with projections suggesting this figure could rise to 18,000 in the future due to the long-term protection offered by the vaccine. However, there is a note of caution, as vaccine uptake has seen a decline since the COVID-19 pandemic, raising concerns about future death rates. The NHS continues to emphasise the importance of both HPV vaccination and cervical screening as central to its ambition to eliminate cervical cancer by 2040.